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Abstract 
 
We present a 43-year-old woman with a nonischemic cardiomyopathy implanted 
with a ventricular assist device (VAD) as bridge to transplant due to severe, “fixed” 
pulmonary hypertension (PH).  Within three months of VAD implant, her “fixed” PH 
had resolved entirely.  Nearly two years later, still supported with a VAD because 
of severe HLA allosensitization, she developed dyspnea and “moderate” aortic 
insufficiency (AI) by standard criteria. Invasive hemodynamics revealed recurrence 
of severe PH in the setting of elevated left-sided filling pressures. We concluded 
the AI was indeed severe and the cause of her symptoms and recurrent PH.  
Despite her noncalcified aortic valve and small body habitus, after a thorough 
assessment, including meticulous annular measurements and appropriate valve 
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sizing, she underwent a transcatheter aortic valve replacement (TAVR) with 
complete resolution of both her AI and recurrent, severe PH.  This case highlights, 
in a single patient, reversal of “fixed” PH with adequate left ventricular unloading, 
that “moderate” AI by standard criteria is often “severe” and must be considered in 
a VAD patient with recurrent PH, and the need for meticulous pre-procedural 
planning for TAVR in patients with VADs, including accurate measurements of the 
aortic annulus to ensure adequate oversizing of the valve.  
 
Keywords:  HVAD, LVAD, TAVR, mechanical circulatory support, pulmonary 
hypertension, aortic insufficiency 
 
Currently, more than 40% of patients undergo bridging with a durable ventricular 
assist device (VAD) prior to heart transplantation for various reasons, including for 
the presence of severe, “fixed” pulmonary hypertension.1 However, a bridging 
strategy with a VAD has potential limitations.  In the perioperative phase of the 
VAD implant, the need for blood product transfusions may result in human 
leukocyte antigen (HLA) antibody sensitization, thus potentially limiting the 
recipient donor pool.2 Moreover, VAD-related complications may ensue while on 
VAD support,3 which may impact transplant candidacy or create new obstacles to 
overcome to achieve a successful transplant outcome.  Herein, we report on a 
challenging case that highlights each of these obstacles and the strategies 
employed to overcome them, all of which occurred in the same patient. 
 
A 43-year-old woman (body surface area of 1.6 m2; body mass index of 24.3 
kg/m2) with a dilated cardiomyopathy underwent Heartware® ventricular assist 
device (HVAD; Heartware International, Inc., Framingham, MA) implant for end-
stage heart failure as a bridge to heart transplantation.  A bridge strategy was 
employed because, in addition to having New York Heart Association Class IV 
heart failure symptoms, we diagnosed severe pulmonary hypertension (PH) and 
found her to be highly sensitized, which would likely require a long wait time on the 
transplant list.  With respect to her allosensitization status, she was highly 
sensitized with major histocompatibility complex (MHC) Class I=100% and Class 
II=100%. Regarding her severe PH, right heart catheterization (RHC) prior to VAD 
implant revealed a pulmonary artery pressure (PAP) of 67/33/47 mm Hg, a 
pulmonary capillary wedge pressure (PCWP) of 26 mm Hg, a cardiac output (CO) 
by thermodilution of 2.12 L/min, and a pulmonary vascular resistance (PVR) of 9.9 
Wood units, which did not significantly improve during acute vasodilator testing 
with intravenous nitroprusside. Pre-operative echocardiography revealed a normal 
sized aortic root with no aortic insufficiency (AI). She underwent a successful 
HVAD implant and her pre-discharge echocardiogram revealed an adequately 
unloaded left ventricle with a closed aortic valve throughout the cardiac cycle.   
 
Approximately one year after HVAD implant, despite what has previously been 
coined “fixed” PH defined as the presence of a PVR > 5 Woods units, a 
transpulmonary gradient > 15 mm Hg, and non-reversible hemodynamics with 
vasodilator administration,4 her PH had nearly resolved entirely.  Specifically, her 
remeasured hemodynamics during a subsequent RHC demonstrated a PAP of 
34/11/20 mm Hg and a PCWP of 11 mm Hg.  As the patient was not treated with 
any PH-targeted medical therapies during this time span, the reversibility of her 
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severe PH, which some may have been inclined to consider to be “fixed” or 
irreversible, could be attributed to the impact of excellent left ventricular unloading 
of sufficient duration. Despite efforts at desensitization with plasmapheresis, IVIG, 
and bortezomib she remained with MHC Class I and Class II antigens of 100%.   
However, many of her titers reduced sufficiently with the desensitization 
treatments to allow us to continue to consider her for heart transplantation, which 
she strongly desired.  
 
Two years after VAD implantation, while continuing to wait for an acceptable HLA 
matched donor, she began to experience a gradual increase in dyspnea.  Repeat 
RHC revealed a recurrence of her severe PH but also now with evidence of 
inadequate left ventricular unloading. Specifically, she had a PAP of 60/30/43 mm 
Hg, a PCWP of 19 mm Hg, CO by thermodilution of 3.07 L/min and a PVR of 7.8 
Wood units.  There was no evidence for VAD thrombosis, her blood pressure was 
well controlled, and increases in her VAD speed did not lower her PCWP (or 
PAPs) further as would normally be expected to occur.  Echocardiography 
revealed the presence of new, at least “moderate” aortic insufficiency (AI) by 
standard grading criteria (Figure 1)5 in the setting of a normal sized aortic root and 
no overt aortic leaflet pathology. However, we were convinced that the continuous 
nature of the “moderate” AI in this clinical context was sufficient to explain her 
heart failure symptoms, elevated left sided filling pressures and recurrence of her 
severe PH,6 which rendered her ineligible yet again for proceeding with 
transplantation.  
 
 
 
Figure 1. Evaluation of aortic insufficiency by echocardiogram. Panel A 
shows at least moderate aortic insufficiency by color Doppler in the 
parasternal long axis view. Panel B illustrates the continuous flow nature of 
the aortic insufficiency by interrogation with continuous wave Doppler.  
 
We decided to pursue transcatheter aortic valve replacement (TAVR) as the least 
invasive means by which to treat her AI while limiting her risk of surgical 
complications including the possibility of requiring additional blood products.   
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However, TAVR for AI, especially in a patient with a VAD and a non-ischemic 
cardiomyopathy, can be fraught with procedural complications, such as valve 
migration in the setting of a non-calcified aortic valve.  Among the strategies to 
consider includes slightly oversizing the aortic valve which is critical to ensure 
sufficient anchoring to reduce the risk of migration while also optimizing valve 
function and hemodynamics.7 In this patient, careful pre-procedural planning to 
ensure safe valve placement included the temporary addition of intravenous 
dobutamine 5u/kg/min and the transient lowering of the patient’s VAD speed from 
2800 RPM to 2300 RPM, both of which were required to induce aortic valve 
opening in an effort to precisely measure her aortic annulus.  Ultimately, a TAVR 
was performed via a right transfemoral approach with a Medtronic (Medtronic, 
Dublin, Ireland) EvolutTM Pro 26 mm valve.  There were no procedural 
complications and the final aortogram revealed a well seated valve with no AI 
(Figure 2). 
 
 
Figure 2. Aortography after transcatheter aortic valve replacement. In the 
Left Anterior Oblique 30 degrees and Cranial 15 degrees view, aortography 
shows a well-seated, bioprosthetic aortic valve without evidence of aortic 
insufficiency and without compression of the left or right coronary arteries.  
 
At six weeks following her TAVR, her symptoms had resolved entirely.  Repeat 
RHC revealed a normalization of her PAPs with a PAP of 31/10/18 mm Hg, a 
PCWP of 6 mm Hg, and a CO of 3.7 L/min. (Table 1 and Figure 3).  Repeat 
echocardiography confirmed a well-seated valve and complete absence of AI. Her 
eligibility for transplant was subsequently re-opened.  
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Table 1. Serial invasive hemodynamic measurements with right heart 
catheterization at critical time points in the patient’s clinical course 
 
Right Heart 
Catheterization 
Prior to 
LVAD 
implant 
One year 
after LVAD 
implant 
Two years after 
LVAD implant 
with “moderate” 
AI 
Six weeks 
after TAVR 
Pulmonary artery 
pressure (mean), 
mm Hg  
67/33 (47) 34/11 (20) 60/30 (43) 31/10 (18) 
Pulmonary 
capillary wedge 
pressure, mm Hg 
26 11 19 6 
Transpulmonary 
pressure 
gradient, mm Hg 
21 9 24 12 
Cardiac output 
by 
thermodilution, 
mm Hg 
2.1 3.4 3.1 3.7 
Pulmonary 
vascular 
resistance, 
Woods units 
9.9 2.6 7.8 3.5 
 
 
Figure 3. HVAD waveforms before and after transcatheter valve replacement. 
Immediately prior to transcatheter aortic valve replacement (Panel A), a 
modest but higher mean flow was present owed to the regurgitant aortic 
insufficiency volume which dropped immediately after transcatheter aortic 
valve replacement (Panel B) due to the elimination of the regurgitant flow 
through the pump.   
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This case illustrates several key teaching points. First, PH in left heart failure is 
nearly always due to persistent elevations in left sided filling pressures yet is also 
nearly always reversible once the filling pressures are lowered, even in the 
presence of a severely elevated, “fixed” PVR.4  Indeed, our patient’s severe PH 
was due to her left heart failure and reversed shortly following her VAD implant.  
When a recurrence of her severe PH occurred, particularly in the setting of 
elevated left sided pressures, a limited and finite list of culprit possibilities exist in a 
VAD patient, one of which is AI.  By eliminating the AI via TAVR and consequently 
re-normalizing her left-sided filling pressures, her severe PH again resolved.  
Second, diagnosing de novo AI and its management in patients with continuous 
flow VADs deserves special attention.  Clinically important AI in VAD supported 
patients may not meet standard severe AI grading criteria, thus requiring a high 
index of suspicion when present such as in our patient whose pre-TAVR imaging 
consistently suggested her AI to be “moderate” and not “severe”.  The inability to 
unload the LV despite increases in VAD speed and the presence of novel, 
echocardiographic parameters8 may be two potential indicators of its true severity. 
Third, the absence of aortic valve opening at time of discharge after LVAD implant 
has been associated with increased risk of the development of AI and may have 
contributed in this case.9 However, the vast majority of patients with an LVAD will 
not develop clinically significant AI even in the absence of intermittent aortic valve 
opening.  This patient required a sufficient VAD speed to maximally unload the LV 
to induce reversibility of her PH; moreover, occasional attempts to lower her VAD 
speed resulted in a recurrence of heart failure symptoms, making the decision to 
maintain a higher VAD speed appropriate.  Lastly, TAVR evaluation in the setting 
of a VAD requires careful pre-procedure planning regarding the valve type, valve 
size, and intra-procedure monitoring for valve migration.  In particular, meticulous 
efforts aimed at precisely measuring aortic annulus dimensions and a slight 
oversizing of the aortic valve may be critical in VAD patients undergoing TAVR.   
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